Curaleaf Hldgs Stock Price, News & Analysis

Curaleaf Holdings, Inc. (CSE: CURA / OTCQX: CURLF) has announced its participation in several investor conferences in November 2022. The events include MJBizCon from November 15-18, where Curaleaf management will host investor meetings, and the CannaVest West Institutional Capital Forum from November 16-17, featuring keynote speeches by Executive Chairman Boris Jordan and CEO Matt Darin. Curaleaf operates in 21 states with 142 dispensaries and is recognized as a leader in the cannabis industry, focusing on consumer products and market expansion.

Curaleaf International announces significant findings from a clinical study on cannabidiol (CBD) treatment for Vestibulodynia (VBD), presented by Chief Scientific Officer Dr. Barbara Pacchetti at a medical cannabis conference on October 21-22, 2022. The study, involving 60 patients, demonstrated improved pain outcomes and muscular tone. Additionally, preclinical studies pointed to CBD's potential in treating psychiatric disorders and migraine pain. Curaleaf focuses on advancing scientific understanding of medical cannabis in collaboration with top academic institutions.

Curaleaf Holdings will announce its financial results for Q2 2022 after market close on November 7, 2022. A conference call is scheduled for 5:00 p.m. ET the same day, where management will discuss the company's operational highlights and respond to questions. Interested parties can access the call by dialing 1-844-512-2926 (U.S.) or join via the webcast available at Curaleaf Events. A replay will be available until November 14, 2022.

Curaleaf has successfully completed its acquisition of Tryke Companies, strengthening its footprint in key markets: Arizona, Nevada, and Utah. This strategic acquisition expands Curaleaf’s operations to 29 cultivation sites and 144 dispensaries across the U.S. The total transaction value amounts to US$181 million, including an initial payment of US$10 million and 2.7 million shares. This deal is anticipated to enhance Curaleaf’s EBITDA margins and cash flow, creating significant growth opportunities in the Western markets.

Curaleaf (CURLF) has completed its acquisition of a 55% stake in Four 20 Pharma GmbH, a licensed German medical cannabis producer. This strategic move positions Curaleaf to leverage the anticipated legalization of adult-use cannabis in Germany, expected in early 2024. Boris Jordan, Executive Chairman, emphasized Curaleaf's unique position as a U.S. MSO in Europe, while Miles Worne, President of Curaleaf International, highlighted Four 20 Pharma's role in accelerating growth in this emerging market. Curaleaf operates in 21 states in the U.S., with plans to expand further into the European market.

Curaleaf Holdings, Inc. (CSE: CURA / OTCQX: CURLF) reminds shareholders to vote their shares for the upcoming annual meeting on September 8, 2022, at 2:00 p.m. (ET). The meeting will be conducted remotely via live webcast. Shareholders must ensure their votes are submitted before the proxy voting deadline of September 6, 2022, at 2:00 p.m. (ET). The company encourages registered shareholders to log in early and emphasizes the importance of voting on proposed resolutions mentioned in the Management Information Circular.

Curaleaf Holdings has strengthened its executive leadership team with the appointments of Ed Kremer as Chief Financial Officer, Camilo Lyon as Chief Investment Officer, and Mitch Hara as Chief Strategy Officer. Kremer brings extensive experience from the cannabis industry and previous roles at Oakley and Beats by Dre. Lyon, with 20 years of finance experience, will lead Capital Markets and Investor Relations. Hara will oversee strategy, including M&A and research. These changes come as Curaleaf aims for long-term growth under CEO Matt Darin, following record earnings in Q2.